Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 11/2010

01-09-2010 | Short Communication

Etanercept treatment in patients with rheumatoid arthritis on dialysis

Authors: Tadashi Nakamura, Syu-ichi Higashi, Kunihiko Tomoda, Michishi Tsukano, Kenzi Arizono, Takamichi Nakamura

Published in: Rheumatology International | Issue 11/2010

Login to get access

Excerpt

Anti-tumour necrosis factor (TNF) α has been shown to be pretty effective in rheumatoid arthritis (RA), but very little is known about its efficacy in renal impairment or on dialysis. Since RA patients with renal failure are difficult to treat, special attentions are required to the possible increase in toxicity and to dose adjustment of the medications used to treat this disease [1]. We report four cases of RA on dialysis with etanercept treatment. …
Literature
1.
Nakamura M, Sakemi T, Nagasawa K (1999) Severe pancytopenia caused by a single administration of low dose methotrexate in a patient undergoing hemodialysis. J Rheumatol 26:1424–1425PubMed
2.
Sin R, Cuchacovich R, Huang W, Espinoza LR (2002) Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol 29:636–637
3.
Yee AM, Pochapin MB (2001) Treatment of sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 135:27–31PubMed
4.
Ortis-Santamaria V, Valls-Roc M, Sanmari M, Olive A (2003) Anti-TNF treatment in secondary amyloidosis. Rheumatology 42:1425–1426CrossRef
5.
Hammoudeh M (2006) Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology 45:357–359CrossRefPubMed
6.
Sugioka Y, Inui K, Koike T (2008) Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. Mod Rheumatol 18:293–295CrossRefPubMed
7.
Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348–365CrossRefPubMed
8.
Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA (2005) The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol 57:1407–1413CrossRefPubMed
Metadata
Title
Etanercept treatment in patients with rheumatoid arthritis on dialysis
Authors
Tadashi Nakamura
Syu-ichi Higashi
Kunihiko Tomoda
Michishi Tsukano
Kenzi Arizono
Takamichi Nakamura
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1452-z

Other articles of this Issue 11/2010

Rheumatology International 11/2010 Go to the issue

Case Report

Long-term efficacy of rituximab in hepatitis C virus-associated cryoglobulinemia

Original Article

Assessment of latent tuberculosis infection in Takayasu arteritis with tuberculin skin test and Quantiferon-TB Gold test

Case Report

Coexisting relapsing polychondritis and sarcoidosis: an unusual association

Original Article

Ultrasonographic assessment of clinically diagnosed trigger fingers

Original Article

Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases

Review

Fibromyalgia and nutrition, what do we know?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits